Aktienanalyse zu Processa Pharmaceuticals Inc (PCSA)PCSAProcessa Pharmaceuticals Inc

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. Its oncology pipeline consists of NGC-Cap and NGC-Iri (also identified as PCS6422 and PCS11T, respectively) and two non-oncology drugs (PCS12852 and PCS499). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan. PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes. Its pipelines also include VT-7208, a Bruton's tyrosine kinase inhibitor therapy for immune-mediated diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, Processa Pharmaceuticals Inc (PCSA) is not a good buy. The stock has dropped 56.19% over the past year and has a low RSI of 31.285, indicating it is oversold. Additionally, the forward P/E ratio is 0, suggesting no earnings growth is expected in the near future. The recent acquisition of Vidya, while potentially beneficial long-term, led to a sharp 38% drop in stock price, highlighting market skepticism. The main risk is the company's negative net income, which stood at -3,265,494 USD in Q2 2026, indicating ongoing financial struggles.